Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GC4002B
- Development stage
- Preclinical
- Lead developer
- GC Biopharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GC4002B is a preclinical quadrivalent influenza vaccine developed by GC Biopharma. It is intended to induce protective immune responses against four influenza virus strains for the prevention of influenza. Public pipeline information identifies the program as preclinical; its vaccine platform, strain composition, formulation, route of administration, and manufacturing details have not been disclosed.
02
Targets
Beyond the preview
Go deeper on GC4002B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GC4002B.